Generation and characterization of two human α/β T cell clones: Recognizing autologous breast tumor cells through an HLA- and TCR/CD3-independent pathway

Paola Nisticò, Piergiuseppe De Berardinis, Stefania Morrone, Tonino Alonzi, Catello Buono, Irene Venturo, Pier Giorgio Natali

Research output: Contribution to journalArticle

Abstract

Cell-mediated immune response to breast tumor has only been marginally investigated. To gain insight into this issue we have developed two clones of distinct phenotype, CD3+ α/β, CD4+, CD8-, CD16-, and CD3+ α/β, CD4-, CD8+, CD16-, respectively, from peripheral blood lymphocytes (PBL) of a breast cancer patient. These effectors, selected on the basis of their cytolytic activity against autologous tumor cells and lack of lysis on NK-sensitive cell lines, preferentially recognize autologous tumor cells. The two clones' cytotoxic activity, while inhibited by anti-LFA-1 mAb, could not be abolished by mAbs to CD3, to class I and class II MHC molecules, and by mAbs to molecules involved in T cell function (i.e., CD4, CD8, CD2). The molecular structure of the α and β T cell receptor chains of the two effector cells, confirmed their clonality and showed that, despite an overlapping killing pattern, they possess distinct TCR α and β chains. These findings demonstrate that breast tumor-specific CTL clones can be generated through current technology and that a α/β effector cell population operating through a HLA-unrestricted and TCR/CD3-independent pathway may be involved in the identification and killing of this tumor.

Original languageEnglish
Pages (from-to)1426-1431
Number of pages6
JournalJournal of Clinical Investigation
Volume94
Issue number4
Publication statusPublished - Oct 1994

Fingerprint

Clone Cells
Breast Neoplasms
T-Lymphocytes
Neoplasms
Lymphocyte Function-Associated Antigen-1
T-Cell Antigen Receptor
Molecular Structure
Natural Killer Cells
Lymphocytes
Technology
Phenotype
Cell Line
Population

Keywords

  • Autologous tumor
  • Breast cancer
  • Cytotoxic activity
  • MHC unrestricted
  • TCR/CD3 independent

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Generation and characterization of two human α/β T cell clones : Recognizing autologous breast tumor cells through an HLA- and TCR/CD3-independent pathway. / Nisticò, Paola; De Berardinis, Piergiuseppe; Morrone, Stefania; Alonzi, Tonino; Buono, Catello; Venturo, Irene; Natali, Pier Giorgio.

In: Journal of Clinical Investigation, Vol. 94, No. 4, 10.1994, p. 1426-1431.

Research output: Contribution to journalArticle

Nisticò, Paola ; De Berardinis, Piergiuseppe ; Morrone, Stefania ; Alonzi, Tonino ; Buono, Catello ; Venturo, Irene ; Natali, Pier Giorgio. / Generation and characterization of two human α/β T cell clones : Recognizing autologous breast tumor cells through an HLA- and TCR/CD3-independent pathway. In: Journal of Clinical Investigation. 1994 ; Vol. 94, No. 4. pp. 1426-1431.
@article{d9e8a59351034b7ebdedf39396d401f4,
title = "Generation and characterization of two human α/β T cell clones: Recognizing autologous breast tumor cells through an HLA- and TCR/CD3-independent pathway",
abstract = "Cell-mediated immune response to breast tumor has only been marginally investigated. To gain insight into this issue we have developed two clones of distinct phenotype, CD3+ α/β, CD4+, CD8-, CD16-, and CD3+ α/β, CD4-, CD8+, CD16-, respectively, from peripheral blood lymphocytes (PBL) of a breast cancer patient. These effectors, selected on the basis of their cytolytic activity against autologous tumor cells and lack of lysis on NK-sensitive cell lines, preferentially recognize autologous tumor cells. The two clones' cytotoxic activity, while inhibited by anti-LFA-1 mAb, could not be abolished by mAbs to CD3, to class I and class II MHC molecules, and by mAbs to molecules involved in T cell function (i.e., CD4, CD8, CD2). The molecular structure of the α and β T cell receptor chains of the two effector cells, confirmed their clonality and showed that, despite an overlapping killing pattern, they possess distinct TCR α and β chains. These findings demonstrate that breast tumor-specific CTL clones can be generated through current technology and that a α/β effector cell population operating through a HLA-unrestricted and TCR/CD3-independent pathway may be involved in the identification and killing of this tumor.",
keywords = "Autologous tumor, Breast cancer, Cytotoxic activity, MHC unrestricted, TCR/CD3 independent",
author = "Paola Nistic{\`o} and {De Berardinis}, Piergiuseppe and Stefania Morrone and Tonino Alonzi and Catello Buono and Irene Venturo and Natali, {Pier Giorgio}",
year = "1994",
month = "10",
language = "English",
volume = "94",
pages = "1426--1431",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "4",

}

TY - JOUR

T1 - Generation and characterization of two human α/β T cell clones

T2 - Recognizing autologous breast tumor cells through an HLA- and TCR/CD3-independent pathway

AU - Nisticò, Paola

AU - De Berardinis, Piergiuseppe

AU - Morrone, Stefania

AU - Alonzi, Tonino

AU - Buono, Catello

AU - Venturo, Irene

AU - Natali, Pier Giorgio

PY - 1994/10

Y1 - 1994/10

N2 - Cell-mediated immune response to breast tumor has only been marginally investigated. To gain insight into this issue we have developed two clones of distinct phenotype, CD3+ α/β, CD4+, CD8-, CD16-, and CD3+ α/β, CD4-, CD8+, CD16-, respectively, from peripheral blood lymphocytes (PBL) of a breast cancer patient. These effectors, selected on the basis of their cytolytic activity against autologous tumor cells and lack of lysis on NK-sensitive cell lines, preferentially recognize autologous tumor cells. The two clones' cytotoxic activity, while inhibited by anti-LFA-1 mAb, could not be abolished by mAbs to CD3, to class I and class II MHC molecules, and by mAbs to molecules involved in T cell function (i.e., CD4, CD8, CD2). The molecular structure of the α and β T cell receptor chains of the two effector cells, confirmed their clonality and showed that, despite an overlapping killing pattern, they possess distinct TCR α and β chains. These findings demonstrate that breast tumor-specific CTL clones can be generated through current technology and that a α/β effector cell population operating through a HLA-unrestricted and TCR/CD3-independent pathway may be involved in the identification and killing of this tumor.

AB - Cell-mediated immune response to breast tumor has only been marginally investigated. To gain insight into this issue we have developed two clones of distinct phenotype, CD3+ α/β, CD4+, CD8-, CD16-, and CD3+ α/β, CD4-, CD8+, CD16-, respectively, from peripheral blood lymphocytes (PBL) of a breast cancer patient. These effectors, selected on the basis of their cytolytic activity against autologous tumor cells and lack of lysis on NK-sensitive cell lines, preferentially recognize autologous tumor cells. The two clones' cytotoxic activity, while inhibited by anti-LFA-1 mAb, could not be abolished by mAbs to CD3, to class I and class II MHC molecules, and by mAbs to molecules involved in T cell function (i.e., CD4, CD8, CD2). The molecular structure of the α and β T cell receptor chains of the two effector cells, confirmed their clonality and showed that, despite an overlapping killing pattern, they possess distinct TCR α and β chains. These findings demonstrate that breast tumor-specific CTL clones can be generated through current technology and that a α/β effector cell population operating through a HLA-unrestricted and TCR/CD3-independent pathway may be involved in the identification and killing of this tumor.

KW - Autologous tumor

KW - Breast cancer

KW - Cytotoxic activity

KW - MHC unrestricted

KW - TCR/CD3 independent

UR - http://www.scopus.com/inward/record.url?scp=0027983563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027983563&partnerID=8YFLogxK

M3 - Article

C2 - 7929817

AN - SCOPUS:0027983563

VL - 94

SP - 1426

EP - 1431

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 4

ER -